RE: Seagen5 Oct 2022 16:15
Hi WTP. Best to ignore RW who needs to get a life frankly. Here's the post from Marcus :-
"Seagen is 5.77% of Redmile`s portfolio, $ 151.11M. SEA-CD40 is a CD40 agonist and recently entered phase 2 clinical trial. The Fc-engineered AvidiMab® technology was introduced into SEA-CD40 in an IgG1 format to improve it functional and cytototic capabilities in cancer
Seagen’s SEA-CD40 is a nonfucosylated CD40 agonist MAb, and phase 1 data just unveiled at the Asco-GI meeting show 44% overall response.
Avidimab, improved functional affinity,superior B cell proliferative capability."
Marcus 419 on POG thread. Thanks Marcus.